A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Clinical trial registration, sponsored by Definium Therapeutics US, Inc., registered 18 May 2026.
Phase 3 · recruiting · n = 165
Tags: Registry, Depression.
Ascend, the DT120 (lysergide tartrate) phase 3 in major depression, is listed as recruiting — the same compound profiled in this week's review
How much weight it carries: Trial registry movements: what is being attempted, not what was found. (Registry, Plans, not results)
Read the original
